Our leadership combines lived rare-disease experience with operational, clinical, and scientific expertise. As caregivers, founders, and research partners, we drive urgent, high-impact progress for children with ATP6AP2 and V-ATPase–related disorders — grounding every decision in both evidence and empathy.

Meet the Team

  • Black-and-white professional headshot of a smiling man in a suit and white shirt.

    Kammy Moalemzadeh

    CO-FOUNDER

    Read Bio
  • A smiling woman with blonde hair, wearing earrings and a patterned blouse, posing against a plain white background.

    Brett Helsham

    CO-FOUNDER

    Read Bio
  • A man with curly hair and glasses smiling at the camera in a grayscale photo.

    Bradlee Heckman

    CHIEF SCIENTIFIC OFFICER

    Read Bio
  • A black-and-white portrait of a young woman with long hair smiling at the camera, wearing earrings and a dark top.

    Dr. Andy Edmondson, MD, PhD

    Head of SCIENTIFIC ADVISORY BOARD

    Read Bio
  • Black and white portrait of a man with dark hair, glasses, a beard, and a mustache, wearing a suit jacket and a checkered shirt, smiling in front of a plain light-colored background.

    Josh Nabatian

    ADVISOR

    Read Bio
  • Black and white professional headshot of a middle-aged man with glasses, wearing a suit jacket and collared shirt, smiling slightly.

    Niall O'Donnell

    SCIENTIFIC ADVISORY BOARD

    Read Bio

  • Alejandra Lozada

    SENIOR RESEACH ASSOCIATE

    Click Here

Rare, but not alone.

There are over 7,000 rare diseases, affecting an estimated 400 million people worldwide—that’s 1 in 10 people. Yet, despite their numbers, rare disease patients remain one of the largest underserved medical communities in the world.

🔹 80% of rare diseases are genetic.
🔹 50% of those affected are children.
🔹 Only 5% of rare diseases have an approved treatment.

That’s not just a statistic—it’s a crisis.

We refuse to accept that. We’re on a mission to change the future of rare disease research and bring real solutions to those who need them most.

Join us. Be part of the breakthrough.